Patent ID: 7919515

Claim:
A method of treatment of diseases and conditions mediated by peroxysome proliferator-activated receptor gamma (PPARγ) wherein said disease or condition is selected from the group consisting of hypertension, obesity, hyperglycemia and atherosclerosis; insulin resistance; type 2 diabetes; peripheral neuropathy, renal insufficiency, and retinopathy, in a mammal subject in need thereof, said method comprising administration to said mammal a compound of formula (I): wherein: W represents COOH group or —COO—C 1 -C 4 -alkyl group; Y represents NH, N—C 1 -C 10 -alkyl, O, or S; Z represents O; X represents O, S, NH, N—C 1 -C 10 -alkyl, N-aryl, NSO 2 —C 1 -C 10 -alkyl, N—SO 2 -aryl, or N—SO 2 -heteroaryl; R 1 to R 8 each independently represent hydrogen atom or a substituent selected from the group consisting of: C 1 -C 4 -alkyl, C 1 -C 4 -alkoxy, C 3 -C 7 -cycloalkyl, C 3 -C 7 -cycloalkoxy, C 1 -C 4 -thioalkoxy, C 3 -C 7 -cyclothioalkoxy, halogen atom, halogen-substituted C 3 -C 7 -cycloalkyl, aryl, heteroaryl, —NO 2 , —CN, —SO 2 —NH 2 , —SO 2 —NH—C 1 -C 4 -alkyl, —SO 2 —N(C 1 -C 4 -alkyl) 2 , —CO—C 1 -C 4 -alkyl, —O—CO—C 1 -C 4 -alkyl, —CO—O—C 1 -C 4 -alkyl, —CO-aryl, —CO—NH 2 , —CO—NH—C 1 -C 4 -alkyl, and —CO—N(C 1 -C 4 -alkyl) 2 ; A represents C 3 -C 7 -cycloalkyl, halogen-substituted C 3 -C 7 -cycloalkyl, aryl, heteroaryl selected from the group consisting of pyrrol-1-yl, pyrrol-2-yl, pyrrol-3-yl, furyl, thienyl, imidazolyl, oxazolyl, thiazolyl, isoxazolyl, 1,2,4-triazolyl, oxadiazolyl, thiadiazolyl, tetrazolyl, pyridinyl, pyrimidinyl, 1,3,5-triazinyl, indolyl, benzo[b]furyl, benzo[b]thienyl, indazolyl, benzimidazolyl, azaindolyl, cynnolyl, isoquinolinyl, and carbazolyl; heterocyclyl, —NH—CO—C 1 -C 4 -alkyl, —N(C 1 -C 4 -alkyl)—CO—C 1 -C 4 -alkyl, —NH—CO-aryl, —N(C 1 -C 4 -alkyl)—CO-aryl, —N(C 1 -C 4 -alkyl)—CO—-C 3 -C 7 -cycloalkyl, —NH—CO—NH 2 , —NH—CO—NH—C 1 -C 4 -alkyl, —NH—CS—NH—C 1 -C 4 -alkyl, —NH—CO—NH-aryl, —NH—CS—NH-aryl, —N(C 1 -C 4 -alkyl)—CO-heteroaryl, —SO 2 —C 1 -C 4 -alkyl, —SO 2 -aryl, or —SO 2 -heteroaryl; wherein said aryl, heteroaryl and heterocyclyl are optionally substituted with one or more substituents independently selected from the group consisting of C 1 -C 4 -alkyl, C 1 -C 4 -alkoxy, C 1 -C 4 -thioalkoxy, ethylenedioxy, CN, halogen and phenyl, said phenyl being optionally substituted with one or more substituents independently selected from C 1 -C 4 -alkyl, C 1 -C 4 -alkoxy and halogen atom; and n represents an integer from 0 to 4, inclusive; enantiomers thereof and pharmaceutically acceptable salts thereof in a therapeutically effective amount.